Effectiveness of a multi-layer silicone-adhesive polyurethane foam dressing as prevention for sacral pressure ulcers in at-risk in-patients: Randomized controlled trial.

Advanced wound dressing Clinical trials Controlled trials General dermatology Pressure ulcers Prevention

Journal

International journal of nursing studies
ISSN: 1873-491X
Titre abrégé: Int J Nurs Stud
Pays: England
ID NLM: 0400675

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 24 07 2021
revised: 20 12 2021
accepted: 03 01 2022
pubmed: 7 2 2022
medline: 11 3 2022
entrez: 6 2 2022
Statut: ppublish

Résumé

There is need for improvement in effective pressure ulcers preventive strategies. To study whether a multi-layer silicone-adhesive polyurethane foam dressing shaped for the sacrum prevents PUs development in addition to standard PU preventive care for at-risk hospitalized patients. Open-label, parallel group, multi-center randomized controlled trial. 709 in-hospital patients at risk for pressure ulcers from 25 medical, surgical, and intensive care units of 12 Italian hospitals. A multi-layer silicone-adhesive polyurethane foam was applied to the sacrum in addition to standard PUs preventive care in the intervention group. In the control group, standard preventive care alone, including systematic pressure ulcer risk assessment, skin assessment three times per day, routine positioning every 4 h, use of active support surface as appropriate, and incontinence skin care, was guaranteed. Primary outcome was incidence of sacral pressure ulcers of any stage at seven days from hospital admission. Secondary outcomes were incidence of sacral pressure ulcers ≥ II stage, number of days needed to PU development, number of skin adverse events due to the foam dressing, number of dressings used for each patient, number of withdrawing patients due to discomfort caused by the foam dressing. Participants were evaluated at baseline and at seven days. In patients admitted to medical units, 15/113 controls and 4/118 in the intervention group developed sacral pressure ulcers (p = 0.010; absolute reduction 9.2%; NNT for benefit 11, 95% CI 6 to 44). In patients admitted to surgical units, 21/144 controls and 8/142 in the intervention group developed sacral pressure ulcers (p = 0.010; absolute reduction 8.9%; NNT for benefit 11 95% CI 6 to 49). Pressure ulcers incidence was not significantly different between the randomization arms (5.2% experimental vs 10.4% control, p = 0.141) in patients admitted to intensive care units. Overall, 46/358 (12.8%) controls and 17/351 (4.8%) in the intervention group developed sacral pressure ulcers (p<0.001; absolute reduction 8%; number needed to treat (NNT) for benefit 12, 95% CI 8 to 26). Incidence of sacral pressure ulcers ≥ II stage did not differ significantly between the two groups. No adverse skin reactions and discomfort attributable to the foam application were reported. A sacral multi-layer silicone-adhesive polyurethane foam in addition to standard preventive care is effective for pressure ulcers prevention in at-risk hospitalized patients admitted to medical and surgical units. ClinicalTrials.gov NCT03900455. The registration (April 1st, 2019) occurred before the first patient was enrolled (October 21st, 2019).

Sections du résumé

BACKGROUND BACKGROUND
There is need for improvement in effective pressure ulcers preventive strategies.
OBJECTIVE OBJECTIVE
To study whether a multi-layer silicone-adhesive polyurethane foam dressing shaped for the sacrum prevents PUs development in addition to standard PU preventive care for at-risk hospitalized patients.
DESIGN METHODS
Open-label, parallel group, multi-center randomized controlled trial.
PARTICIPANTS AND SETTING METHODS
709 in-hospital patients at risk for pressure ulcers from 25 medical, surgical, and intensive care units of 12 Italian hospitals.
METHODS METHODS
A multi-layer silicone-adhesive polyurethane foam was applied to the sacrum in addition to standard PUs preventive care in the intervention group. In the control group, standard preventive care alone, including systematic pressure ulcer risk assessment, skin assessment three times per day, routine positioning every 4 h, use of active support surface as appropriate, and incontinence skin care, was guaranteed. Primary outcome was incidence of sacral pressure ulcers of any stage at seven days from hospital admission. Secondary outcomes were incidence of sacral pressure ulcers ≥ II stage, number of days needed to PU development, number of skin adverse events due to the foam dressing, number of dressings used for each patient, number of withdrawing patients due to discomfort caused by the foam dressing. Participants were evaluated at baseline and at seven days.
RESULTS RESULTS
In patients admitted to medical units, 15/113 controls and 4/118 in the intervention group developed sacral pressure ulcers (p = 0.010; absolute reduction 9.2%; NNT for benefit 11, 95% CI 6 to 44). In patients admitted to surgical units, 21/144 controls and 8/142 in the intervention group developed sacral pressure ulcers (p = 0.010; absolute reduction 8.9%; NNT for benefit 11 95% CI 6 to 49). Pressure ulcers incidence was not significantly different between the randomization arms (5.2% experimental vs 10.4% control, p = 0.141) in patients admitted to intensive care units. Overall, 46/358 (12.8%) controls and 17/351 (4.8%) in the intervention group developed sacral pressure ulcers (p<0.001; absolute reduction 8%; number needed to treat (NNT) for benefit 12, 95% CI 8 to 26). Incidence of sacral pressure ulcers ≥ II stage did not differ significantly between the two groups. No adverse skin reactions and discomfort attributable to the foam application were reported.
CONCLUSION CONCLUSIONS
A sacral multi-layer silicone-adhesive polyurethane foam in addition to standard preventive care is effective for pressure ulcers prevention in at-risk hospitalized patients admitted to medical and surgical units.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT03900455. The registration (April 1st, 2019) occurred before the first patient was enrolled (October 21st, 2019).

Identifiants

pubmed: 35124474
pii: S0020-7489(22)00001-3
doi: 10.1016/j.ijnurstu.2022.104172
pii:
doi:

Substances chimiques

Adhesives 0
Polyurethanes 0
Silicones 0
polyurethane foam 9009-54-5

Banques de données

ClinicalTrials.gov
['NCT03900455']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

104172

Investigateurs

Fabiola Bandi (F)
Manuela Batani (M)
Giovanna Bertin (G)
Luana Bianchi (L)
Monica Carmagnini (M)
Silvia Cedioli (S)
Stefano Colognese (S)
Consuelo Morena (C)
Fabio D'Alessandro (F)
Mirella Fontana (M)
Ludovica Galassi (L)
Monica Gridelli (M)
Paola Magnani (P)
Mattia Morri (M)
Barbara Ortolani (B)
Maurizio Scialla (M)
Pamela Stanga (P)
Paola Toselli (P)
Sarah Zanelli (S)

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared. Smith & Nephew signed an agreement to supply the dressings free of charge for all the patients in the study without influencing any phase of the research project.

Auteurs

Cristiana Forni (C)

Head of the Nursing and Allied Profession Research Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address: cristiana.forni@ior.it.

Domenica Gazineo (D)

Staff Nurse, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola - Malpighi, Bologna, Italy. Electronic address: domenica.gazineo@aosp.bo.it.

Elisabetta Allegrini (E)

Nurse Executive of Health Professions, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: elisabetta.allegrini@aovr.veneto.it.

Tatiana Bolgeo (T)

Coordinator of HTA Unit, Department of Research, Training and Innovation, Azienda Ospedaliera Nazionale S.S. Antonio e Biagio e C. Arrigo, Alessandria, Italy. Electronic address: tbolgeo@ospedale.al.it.

Anna Brugnolli (A)

Head of Centre of Higher Education for Health Sciences, Azienda Provinciale per I Servizi Sanitari di Trento, Trento, Italy. Electronic address: anna.brugnolli@apss.tn.it.

Federica Canzan (F)

Associate Professor, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. Electronic address: federica.canzan@univr.it.

Paolo Chiari (P)

Associate Professor Alma Mater, University of Bologna, Bologna, Italy. Electronic address: paolo.chiari@unibo.it.

Andrea Evangelista (A)

General Affairs Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address: andrea.evangelista@ior.it.

Anna Maria Grugnetti (AM)

Coordinator of Degree and Master's Degree Courses in Health Professions and Research, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: a.grugnetti@smatteo.pv.it.

Giuseppina Grugnetti (G)

Nurse Executive of Health Professions, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: g.grugnetti@smatteo.pv.it.

Monica Guberti (M)

Nurse Executive of Health Professions, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy. Electronic address: monica.guberti@ausl.re.it.

Maria Matarese (M)

Associate Professor, Research Unit of Nursing Sciences, Campus Bio-Medico, University of Rome, Roma, Italy. Electronic address: m.matarese@unicampus.it.

Elisabetta Mezzalira (E)

Research Fellow, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. Electronic address: elisabetta.mezzalira@univr.it.

Lara Pierboni (L)

Organizational Representative, Nursing and Technical Direction, AUSL Romagna ambito di Rimini, Rimini, Italy. Electronic address: lara.pierboni@auslromagna.it.

Letizia Prosperi (L)

Clinical teacher, Centre of Higher Education for Health Sciences, Azienda Provinciale per I Servizi Sanitari di Trento, Trento, Italy. Electronic address: letizia.prosperi@apss.tn.it.

Barbara Sofritti (B)

Chief Nurse, Orthopaedics, Ospedale Maggiore AUSL Bologna, Italy. Electronic address: b.sofritti@ausl.bo.it.

Cristina Tovazzi (C)

Nurse Executive, Provincial Hospital Service, Azienda Provinciale per I Servizi Sanitari di Trento, Trento, Italy. Electronic address: cristina.tovazzi@apss.tn.it.

Silvia Vincenzi (S)

Coordinator of the Master of Science in Nursing, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: silvia.vincenzi@univr.it.

Paola Zambiasi (P)

Chief Nurse, Care Process Governance Service, Azienda Provinciale per I Servizi Sanitari di Trento, Trento, Italy. Electronic address: paola.zambiasi@apss.tn.it.

Carlotta Zoffoli (C)

Organizational Representative, Wound Care Specialist Network, AUSL Romagna ambito di Cesena, Cesena, Italy. Electronic address: carlotta.zoffoli@auslromagna.it.

Elisa Ambrosi (E)

Senior Assistant Professor, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. Electronic address: elisa.ambrosi_01@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH